MedTrace Logo

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

NCT00963924 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2018-02-06

Study results available
· View outcomes & findings →

Summary

This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia. We will test the hypotheses that D-cycloserine will significantly improve cognitive performance, negative symptoms, and measures of functioning compared to placebo when combined with eight weeks of cognitive remediation. We expect that these effects will persist when assessed at six-month follow up.

Conditions

Interventions

DRUG

D-cycloserine

50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.

DRUG

Placebo

Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.

BEHAVIORAL

Cognitive Remediation

40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Donald C. Goff, M.D. · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00963924 on ClinicalTrials.gov